Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, AERI is expected to report 3Q20 loss of $ 0.8 per share from revenue of $ 19.71 million.
For the full year, analysts anticipate top line of $ 80.43 million, while looking forward to loss of $ 3.2 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 100.00 million ~ $ 110.00 million
Click Here For More Historical Outlooks Of Aerie Pharmaceuticals, Inc.
Previous Quarter Performance
Aerie Pharmaceuticals, Inc. outlined loss for the second quarter of $ 1.05 per share, from the revenue of $ 18.03 million. The quarterly revenues grew 13.83 percent compared with the same quarter last year. According to street consensus, AERI was expected to report 2Q20 loss of $ 0.80 per share from revenue of $ 17.45 million. The bottom line results missed street analysts by $ 0.25 or 31.25 percent, at the same time, top line results outshined analysts by $ 0.58 million or 3.32 percent.
Stock Performance
Shares of Aerie Pharmaceuticals, Inc. traded up $ 0.00 or 0.00 percent on Wednesday, reaching $ 10.89 with volume of 664.20 thousand shares. Aerie Pharmaceuticals, Inc. has traded high as $ 11.46 and has cracked $ 10.88 on the downward trend
The closing price of $ 10.89, representing a 20.87 % increase from the 52 week low of $ 9.01 and a 58.53 % decrease over the 52 week high of $ 26.26.
The company has a market capital of $ 506.54 million and is part of the Healthcare sector and Drug Manufacturers – Major industry.
Recent Analyst recommendations
- On 19th October 2020, downgraded by Bank of America to Underperform from Neutral rating
- On 8th September 2020, initiated by Guggenheim at Buy rating, with $ 20.00 target price.
Conference Call
Aerie Pharmaceuticals, Inc. will be hosting a conference call at 5:00 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.aeriepharma.com
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The companys advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension.
